Loading…
2 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Inova In Vitro | Healthcare Services | 27.6% | 88th pct | 268 |
| JMP | Pharma | 20.8% | 62nd pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Inova In Vitro | JMP |
|---|---|---|
| Margins | ||
| Gross Margin | 33.0% | 21.0% |
| EBITDA Margin | 27.6% | 20.8% |
| EBITDAR | 3,903 | 2,017 |
| EBITDAR Margin | 27.6% | 22.3% |
| EBIT Margin | 27.6% | 20.3% |
| Net Profit Margin | 28.0% | 23.1% |
| Operating Expense % of Sales | 5.4% | 0.2% |
| Returns | ||
| Return on Assets (ROA) | 87.7% | 36.3% |
| Return on Equity (ROE) | 97.0% | 45.0% |
| ROIC [EBIT / Invested Capital] | 142.2% | 40.4% |
| Leverage & debt balances | ||
| Debt-to-Assets | 0.0% | 4.1% |
| Debt-to-Equity | 0.00x | 0.05x |
| Debt-to-EBITDA | 0.00x | 0.12x |
| Equity-to-Assets | 90.5% | 80.7% |
| Net Debt | -1,334 | -83 |
| Cash & Equivalents | 1,334 | 317 |
| Total Debt | N/A | 233 |
| Liquidity & working capital | ||
| Current Ratio | 8.91x | 3.79x |
| Quick Ratio | 7.91x | 3.79x |
| Cash Ratio | 3.10x | 0.36x |
| Total Current Assets | 3,833 | 3,317 |
| Total Current Liabilities | 430 | 876 |
| Inventory | 432 | N/A |
| Trade Receivables | 2,067 | 414 |
| Trade Payables | 430 | 876 |
| Net Working Capital | 3,403 | 2,441 |
| Net Working Capital % of Revenue | 24.1% | 27.0% |
| Trade Working Capital | 2,069 | -462 |
| Trade Working Capital % of Revenue | 14.6% | -5.1% |
| Change in Trade Working Capital | N/A | N/A |
| Turnover & efficiency | ||
| Inventory Turnover | 21.91x | N/A |
| Days Inventory Outstanding (DIO) | 16.7 | N/A |
| Receivables Turnover | 6.84x | 21.82x |
| Days Sales Outstanding (DSO) | 53.4 | 16.7 |
| Payables Turnover | 22.01x | 8.15x |
| Days Payable Outstanding (DPO) | 16.6 | 44.8 |
| Cash Conversion Cycle | 53.5 days | -28.0 days |
| Asset Turnover | 3.14x | 1.57x |
| Cash flow & dividends | ||
| Operating Cash Flow | 3,788 | 2,319 |
| Free Cash Flow (OCF − Capex proxy) | 3,648 | 1,077 |
| Cash Conversion (OCF / EBITDA) | 97.1% | 123.3% |
| Dividends Declared | 3,822 | N/A |
| Dividend Payout Ratio | 96.7% | N/A |